Takeda Pipeline, Products, Performance, Potential : Market Research Report

Takeda Pipeline, Products, Performance, Potential

Published by: Espicom Healthcare Intelligence

Published: Nov. 10, 2009 - 124 Pages

Latest Results
EXECUTIVE SUMMARY: Introduction; Current Financial Position; Business Segment Performance; Geographic Segment Performance; Company Strategy; R&D Strategy; Mergers, Acquisitions and Divestitures; Key Agreements; Discontinued Agreements; Production; Product Performance Forecasts; Pipeline Analysis; Conclusions
THERAPEUTIC AREA FOCUS
R&D PIPELINE
METABOLIC: Marketed Products; Actos; Basen; Others; R&D Projects; Alogliptin; Cetilistat; SYR-472; TAK-100; TAK-875; Growth Forecast
GASTROINTESTINAL: Marketed Products; Amitiza; Kapidex; Takepron/Prevacid/Zoton; Others; R&D Projects; TAK-438; Growth Forecast
CARDIOVASCULAR: Marketed Products; Blopress; Others; R&D Projects; Azilsartan; Omacor; TAK-442; TAK-591; Growth Forecast
ANTICANCER: Marketed Products; Velcade; Others; R&D Projects; CBP-501; Conatumumab; MLN4924; MLN8237; MLN9708; Motesanib Disphosphate; Panitumumab; TAK-285; TAK-385; TAK-448; TAK-593; TAK-683; TAK-700; TAK-701; TAK-901; Tandutinib; TRM-1; Growth Forecast
MUSCULOSKELETAL: Marketed Products; Benet; Enbrel; Others; Growth Forecast
CENTRAL NERVOUS SYSTEM: Marketed Products; Catena/Sovrima; Rozerem; Others; R&D Projects; Lu AA21004; Lu AA24530; Ruboxistaurin; TAK-065; TAK-428; TAK-937; XEN401; Growth Forecast
OTHERS: Marketed Products; R&D Projects; Hematide; MLN0415; TAK-187; Vedolizumab
APPENDIX 1 - FINANCIAL PERFORMANCE: Full Year Results 2008
APPENDIX 2 - KEY CORPORATE EVENTS
APPENDIX 3 - KEY AGREEMENTS: 3M Pharmaceuticals; Abbott; Affymax Inc; Alnylam Pharmaceuticals Inc; Amgen; Andrx Corporation; CanBas Co Ltd; Cephalon Inc; Eli Lilly; Evotec; Faust Pharmaceuticals; Galaxy Biotech; Human Genome Sciences; Japan Poliomyelitis Research Institute; Kyowa Hakko Kirin; LG Life Sciences Ltd; Lundbeck; Merck KGaA; Norgine BV; Novartis; Pfizer; PPD Inc; Pronova Biocare AS; Santhera Pharmaceuticals AG; Shire; Sucampo Pharmaceuticals Inc; Terumo Corp; Tobira Therapeutics; Xenon Pharmaceuticals; XOMA; Others
APPENDIX 4 - INFRASTRUCTURE: Research And Development Facilities; Manufacturing Facilities
APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES/JOINT VENTURES: Subsidiaries; Joint-venture Companies
APPENDIX 6 - PRODUCT INDEX
Index of Tables: Principal Operating Results; Capital Expenditure By Business Area; Sales By Business Area; Operating Income By Business Area; Identifiable Assets By Business Area; Sales By Destination; Sales By Origin; Operating Income By Geographic Segment; Recent Product Approvals; Major Products, Therapeutic Areas and Sales; Domestic Pipeline; Major Metabolic Products, 2009; Major Gastrointestinal Products, 2009; Major Cardiovascular Products, 2009; Major Anticancer Products, 2009; Major Musculoskeletal Products, 2009; Major CNS Products, 2008; Other Products Sales, 2009
Index of Charts: Sales By Business Area, 2009; Operating Income By Business Area; Sales By Destination; Sales By Origin; Operating Income By Geographic Segment; Sales of Major Products (2004A-2014E); Sales of Top Ten Products, 2009; Overseas Pipeline; Actos Sales (2004A-2014E); Basen Sales (2004A-2014E); Alogliptin Sales (2010E-2014E); Amitiza Sales (2004A-2014E); Kapidex Sales (2010E-2014E); Takepron Sales (2004A-2014E); Blopress Sales (2004A-2014E); Velcade Sales (2005E-2015E); Motesanib Disphosphate Sales (2010E-2014E); Panitumumab Sales (2010-2014E); Benet Sales (2004A-2014E); Enbrel Sales (2006A-2014E); Catena/Sovrima Sales (2010E-2014E); Rozerem Sales (2004A-2014E); Sales, Costs and Operating Income; Profitability and Research Ratios; R&D Expenditure and Capital Expenditure; Current Assets, Liabilities and Ratio; Assets, Cash and Liquidity; Employees and Productivity

Abstract

Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

2/15/2012 - 31

Takeda Pipeline, Products, Performance, Potential

Table of Contents

Abstract